Sarepta Therapeutics (SRPT) Hits New 1-Year High and Low on Analyst Upgrade

Sarepta Therapeutics (NASDAQ:SRPT)’s share price reached a new 52-week high and low on Wednesday after Leerink Swann raised their price target on the stock from $88.00 to $121.00. Leerink Swann currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $95.67 and last traded at $94.81, with a volume of 42782 shares trading hands. The stock had previously closed at $92.22.

A number of other equities research analysts also recently commented on the stock. Credit Suisse Group lifted their price target on shares of Sarepta Therapeutics from $81.00 to $100.00 and gave the stock an “outperform” rating in a report on Tuesday, March 13th. SunTrust Banks boosted their target price on shares of Sarepta Therapeutics to $95.00 and gave the company a “buy” rating in a report on Friday, March 16th. Morgan Stanley downgraded shares of Sarepta Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the company from $64.00 to $87.00 in a report on Wednesday, March 21st. Royal Bank of Canada initiated coverage on shares of Sarepta Therapeutics in a report on Monday, January 22nd. They issued an “outperform” rating for the company. Finally, Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 7th. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $86.88.

Get Sarepta Therapeutics alerts:

Several hedge funds and other institutional investors have recently bought and sold shares of SRPT. Bank of Montreal Can lifted its position in shares of Sarepta Therapeutics by 1.3% during the fourth quarter. Bank of Montreal Can now owns 85,707 shares of the biotechnology company’s stock worth $4,770,000 after purchasing an additional 1,103 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in Sarepta Therapeutics by 7.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 289,349 shares of the biotechnology company’s stock valued at $16,100,000 after acquiring an additional 20,796 shares in the last quarter. Strs Ohio raised its holdings in Sarepta Therapeutics by 34.8% in the fourth quarter. Strs Ohio now owns 6,200 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 1,600 shares in the last quarter. Legato Capital Management LLC acquired a new stake in Sarepta Therapeutics in the fourth quarter valued at $234,000. Finally, Jennison Associates LLC raised its holdings in Sarepta Therapeutics by 0.6% in the fourth quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock valued at $63,998,000 after acquiring an additional 6,357 shares in the last quarter. 85.21% of the stock is currently owned by institutional investors and hedge funds.

The firm has a market cap of $6.10 billion, a PE ratio of -58.06 and a beta of 1.34. The company has a debt-to-equity ratio of 0.55, a quick ratio of 12.28 and a current ratio of 13.37.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.23). The company had revenue of $64.60 million during the quarter, compared to analyst estimates of $65.31 million. Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. The company’s revenue was up 295.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.57) earnings per share. research analysts predict that Sarepta Therapeutics will post -1.79 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Leave a Reply

Your email address will not be published. Required fields are marked *